Search

Your search keyword '"Blau, Igor Wolfgang"' showing total 13 results
Start Over Author "Blau, Igor Wolfgang" Journal bone marrow transplantation
13 results on '"Blau, Igor Wolfgang"'

1. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Maffini, Enrico, primary, Labopin, Myriam, additional, Kröger, Nicolaus, additional, Finke, Jürgen, additional, Stelljes, Matthias, additional, Schroeder, Thomas, additional, Einsele, Herman, additional, Tischer, Johanna, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang, additional, Brecht, Arne, additional, Rösler, Wolf, additional, Dreger, Peter, additional, Schäfer-Eckart, Kerstin, additional, Passweg, Jakob, additional, Blau, Igor Wolfgang, additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2024
Full Text
View/download PDF

2. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype

Author

Poiré, Xavier, primary, Labopin, Myriam, additional, Polge, Emmanuelle, additional, Ganser, Arnold, additional, Socié, Gérard, additional, Gedde-Dahl, Tobias, additional, Forcade, Edouard, additional, Finke, Jürgen, additional, Chalandon, Yves, additional, Bulabois, Claude-Eric, additional, Yakoub-Agha, Ibrahim, additional, Aljurf, Mahmoud, additional, Kröger, Nicolaus, additional, Blau, Igor Wolfgang, additional, Nagler, Arnon, additional, Esteve, Jordi, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

3. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, primary, Labopin, Myriam, additional, Gedde-Dahl, Tobias, additional, Ganser, Arnold, additional, Stelljes, Matthias, additional, Craddock, Charles, additional, Wagner-Drouet, Eva Maria, additional, Versluis, Jurjen, additional, Schroeder, Thomas, additional, Blau, Igor Wolfgang, additional, Wulf, Gerald. G., additional, Dreger, Peter, additional, Olesen, Gitte, additional, Sengeloev, Henrik, additional, Kröger, Nicolaus, additional, Potter, Victoria, additional, Forcade, Edouard, additional, Passweg, Jakob, additional, de Latour, Régis Peffault, additional, Maertens, Johan, additional, Wilson, Keith M. O., additional, Bourhis, Jean Henri, additional, Finke, Juergen, additional, Brissot, Eolia, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Savani, Bipin P., additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

4. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT

Author

Nagler, Arnon, primary, Labopin, Myriam, additional, Kröger, Nicolaus, additional, Schroeder, Thomas, additional, Gedde-Dahl, Tobias, additional, Eder, Matthias, additional, Franke, Georg-Nikolaus, additional, Blau, Igor Wolfgang, additional, Salmenniemi, Urpu, additional, Socie, Gerard, additional, Schetelig, Johannes, additional, Stelljes, Matthias, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

5. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype

Author

Poiré, Xavier, Labopin, Myriam, Polge, Emmanuelle, Ganser, Arnold, Socié, Gérard, Gedde-Dahl, Tobias, Forcade, Edouard, Finke, Jürgen, Chalandon, Yves, Bulabois, Claude-Eric, Yakoub-Agha, Ibrahim, Aljurf, Mahmoud, Kröger, Nicolaus, Blau, Igor Wolfgang, Nagler, Arnon, Esteve, Jordi, and Mohty, Mohamad

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p= 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p= 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p= 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p= 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.

Published
2024
Full Text
View/download PDF

6. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, Labopin, Myriam, Gedde-Dahl, Tobias, Ganser, Arnold, Stelljes, Matthias, Craddock, Charles, Wagner-Drouet, Eva Maria, Versluis, Jurjen, Schroeder, Thomas, Blau, Igor Wolfgang, Wulf, Gerald. G., Dreger, Peter, Olesen, Gitte, Sengeloev, Henrik, Kröger, Nicolaus, Potter, Victoria, Forcade, Edouard, Passweg, Jakob, de Latour, Régis Peffault, Maertens, Johan, Wilson, Keith M. O., Bourhis, Jean Henri, Finke, Juergen, Brissot, Eolia, Bazarbachi, Ali, Giebel, Sebastian, Savani, Bipin P., Nagler, Arnon, Ciceri, Fabio, and Mohty, Mohamad

Abstract

The intensity of the conditioning regimen given before allogeneic hematopoietic cell transplantation (allo-HCT) can vary substantially. To confirm the ability of the recently developed transplant conditioning intensity (TCI) score to stratify the preparative regimens of allo-HCT, we used an independent and contemporary patient cohort of 4060 transplant recipients with acute myeloid leukemia meeting inclusion criteria from the discovery study (allo-HCT in first complete remission, matched donor), but who were allografted in a more recent period (2018–2021) and were one decade older (55–75 years, median 63.4 years), we assigned them to a TCI category (low n= 1934, 48%; intermediate n= 1948, 48%, high n= 178, 4%) according to the calculated TCI score ([1–2], [2.5–3.5], [4–6], respectively), and examined the validity of the TCI category in predicting early non-relapse mortality (NRM), 2-year NRM and relapse (REL). In the unadjusted comparison, the TCI index provided a significant risk stratification for d100 and d180 NRM, NRM and REL risk. In the multivariate analysis adjusted for significant variables, there was an independent association of TCI with early NRM, NRM and REL. In summary, we confirm in contemporary treated patients that TCI reflects the conditioning regimen related morbidity and anti-leukemic efficacy satisfactorily and across other established prognostic factors.

Published
2024
Full Text
View/download PDF

7. The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT

Author

Tournilhac, Olivier, primary, van Gelder, Michel, additional, Eikema, Dirk-Jan, additional, Zinger, Nienke, additional, Dreger, Peter, additional, Bornhäuser, Martin, additional, Vucinic, Vladan, additional, Scheid, Christof, additional, Cornelissen, Jan J., additional, Schroeder, Thomas, additional, Jindra, Pavel, additional, Sengeloev, Henrik, additional, Nguyen Quoc, Stephanie, additional, Stelljes, Matthias, additional, Blau, Igor Wolfgang, additional, Mayer, Jiri, additional, Paneesha, Shankara, additional, Chevallier, Patrice, additional, Forcade, Edouard, additional, Kröger, Nicolaus, additional, Blaise, Didier, additional, Gribben, John, additional, Nielsen, Bendt, additional, Johansson, Jan-Erik, additional, Kyriakou, Charalampia, additional, Beguin, Yves, additional, Pioltelli, Pietro, additional, Sampol, Antònia, additional, McLornan, Donal P., additional, Schetelig, Johannes, additional, Hayden, Patrick J., additional, and Yakoub-Agha, Ibrahim, additional

Published
2023
Full Text
View/download PDF

8. Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Author

Nagler, Arnon, primary, Peczynski, Christophe, additional, Dholaria, Bhagirathbhai, additional, Labopin, Myriam, additional, Valerius, Thomas, additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Reinhardt, Hans Christian, additional, Finke, Jürgen, additional, Franke, Georg-Nikolaus, additional, Ciceri, Fabio, additional, Verbeek, Mareike, additional, Blau, Igor Wolfgang, additional, Bornhäuser, Martin, additional, Spyridonidis, Alexandros, additional, Bug, Gesine, additional, Bazarbachi, Ali, additional, Schmid, Christophe, additional, Yakoub-Agha, Ibrahim, additional, Savani, Bipin N., additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

9. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Author

Nagler, Arnon, primary, Peczynski, Christophe, additional, Dholaria, Bhagirathbhai, additional, Labopin, Myriam, additional, Valerius, Thomas, additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Reinhardt, Hans Christian, additional, Finke, Jürgen, additional, Franke, Georg-Nikolaus, additional, Ciceri, Fabio, additional, Verbeek, Mareike, additional, Blau, Igor Wolfgang, additional, Bornhäuser, Martin, additional, Spyridonidis, Alexandros, additional, Bug, Gesine, additional, Bazarbachi, Ali, additional, Schmid, Christophe, additional, Yakoub-Agha, Ibrahim, additional, Savani, Bipin N., additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

10. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis

Author

Rodríguez-Arbolí, Eduardo, primary, Labopin, Myriam, additional, Eder, Matthias, additional, Brecht, Arne, additional, Blau, Igor Wolfgang, additional, Huynh, Anne, additional, Forcade, Edouard, additional, Tischer, Johanna, additional, Bethge, Wolfgang, additional, Bondarenko, Sergey, additional, Verbeek, Mareike, additional, Bulabois, Claude Eric, additional, Einsele, Hermann, additional, Stölzel, Friedrich, additional, Savani, Bipin, additional, Spyridonidis, Alexandros, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Brissot, Eolia, additional, Schmid, Christoph, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

12. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

Author

Paviglianiti, Annalisa, primary, Labopin, Myriam, additional, Blaise, Didier, additional, Socié, Gerard, additional, Bulabois, Claude Eric, additional, Lioure, Bruno, additional, Ceballos, Patrice, additional, Blau, Igor Wolfgang, additional, Guillerm, Gaelle, additional, Maertens, Johan, additional, Chevallier, Patrice, additional, Huynh, Anne, additional, Turlure, Pascal, additional, Deconinck, Eric, additional, Forcade, Edouard, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

13. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

Author

Paviglianiti, Annalisa, Labopin, Myriam, Blaise, Didier, Socié, Gerard, Bulabois, Claude Eric, Lioure, Bruno, Ceballos, Patrice, Blau, Igor Wolfgang, Guillerm, Gaelle, Maertens, Johan, Chevallier, Patrice, Huynh, Anne, Turlure, Pascal, Deconinck, Eric, Forcade, Edouard, Nagler, Arnon, and Mohty, Mohamad

Abstract

The association of Cyclosporine A (CsA) and mycophenolate mofetil (MMF) has increased in the setting of reduced intensity conditioning (RIC). Nevertheless, the use of CsA or CsA+MMF has not been reported in a large and uniform cohort. We analyzed 497 patients with acute myeloid leukemia in complete remission (CR) who underwent matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT). All patients received a fludarabine busulfan RIC regimen and anti-thymocyte globulin (ATG) with either CsA alone or in combination with MMF. The cumulative incidence (CI) of grade II–IV acute GvHD was 27% (95% CI 21–33%) for CsA and 33% (95% CI 27–38%) for CsA+MMF (p= 0.25). The 2-year CI of chronic GvHD was 38% (95% CI 31–45%) and 33% (95% CI 28–39%) for the CsA and the CsA+MMF group, respectively (p= 0.26). On multivariate analysis, no statistically significant differences with respect to relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), acute and chronic GvHD were found between the two groups, also when conducting a subgroup analysis in peripheral blood stem cells (PBSC) recipients. Our results support the importance of randomized trial to identify patients who could benefit from the addition of MMF in MUD HSCT.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results